59820-83-6

Usage

Uses

Used in Organic Chemistry:
7-Methyl-6-nitro-1,4-benzodioxane serves as a versatile reactant in the field of organic chemistry, particularly for a variety of chemical reactions. Its distinctive structure allows it to participate in numerous synthesis processes, making it a valuable component in the creation of other organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 7-Methyl-6-nitro-1,4-benzodioxane is utilized as a key intermediate in the development and synthesis of various pharmaceutical products. Its unique chemical properties make it a promising candidate for the production of new drugs and medicinal agents.
Used in Agrochemical Industry:
The agrochemical industry also benefits from the application of 7-Methyl-6-nitro-1,4-benzodioxane, where it is employed in the synthesis of agrochemicals. Its reactivity and chemical structure contribute to the development of effective products for agricultural use.
Used in Dye and Pigment Production:
7-Methyl-6-nitro-1,4-benzodioxane is also used as a precursor in the manufacturing process of certain dyes and pigments. Its chemical composition plays a crucial role in the formation of colorants used in various industries, including textiles, plastics, and printing.
It is crucial to handle 7-Methyl-6-nitro-1,4-benzodioxane with care due to its potential health and environmental risks if mismanaged. Proper management and usage protocols are essential to ensure safety in its applications across different industries.

InChI:InChI=1/C9H9NO4/c1-6-4-8-9(14-3-2-13-8)5-7(6)10(11)12/h4-5H,2-3H2,1H3

Upstream product

• 33632-35-8 6-methyl-2,3-dihydrobenzo[b][1,4]dioxine 
• 452-86-8 4-methyl-1,2-dihydroxybenzene 

Downstream Products

• 59820-84-7 7-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-amine 

Relevant academic research and scientific papers

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY

Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.

Indolocarbazole anticancer agents and methods of using same

The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity. 1

Indolocarbazole anticancer agents and methods of using them

The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity. 1